12:00 AM
 | 
Jun 18, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Canagliflozin: Phase III data

The double-blind, international Phase III DIA3009 trial in 1,450 Type II diabetics with inadequate glycemic control on maximally effective doses of metformin showed once-daily 300 mg oral canagliflozin met the primary endpoint of reducing HbA1c from baseline to week 52 vs. glimepiride (0.93% vs. 0.81%). The once-daily 100 mg dose of canagliflozin was non-inferior but not superior to glimepiride on the endpoint (0.82%). On secondary endpoints, low- and high-dose canagliflozin led to significantly greater reductions in...

Read the full 356 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >